C2I Genomics Inc. Sustainability Profile
C2I Genomics Inc., headquartered in the United States, is a pioneering force in the genomics industry, specialising in advanced genomic solutions for cancer detection and monitoring. Founded in 2020, the company has rapidly established itself as a leader in the field, leveraging cutting-edge technology to provide unique insights into tumour evolution and treatment response. C2I Genomics offers a range of innovative products and services, including comprehensive genomic profiling and liquid biopsy solutions, which are designed to enhance precision medicine. Their proprietary algorithms and data analytics capabilities set them apart, enabling healthcare providers to make informed decisions based on real-time genomic data. With a commitment to improving patient outcomes, C2I Genomics continues to make significant strides in the oncology landscape, positioning itself as a trusted partner in the fight against cancer.
DitchCarbon Score
How does C2I Genomics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
C2I Genomics Inc.'s score of 23 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
C2I Genomics Inc.'s reported carbon emissions
C2I Genomics Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported emissions figures. The company is a current subsidiary of Veracyte, Inc., which may influence its climate commitments and initiatives. As of now, C2I Genomics Inc. has not established any documented reduction targets or climate pledges. The lack of specific emissions data and reduction initiatives suggests that the company is in the early stages of developing its climate strategy. Given its affiliation with Veracyte, Inc., it is possible that C2I Genomics may align its climate commitments with those of its parent company, although no specific details have been provided. The company’s future climate actions will be crucial in addressing its environmental impact and contributing to broader industry sustainability goals.
How Carbon Intensive is C2I Genomics Inc.'s Industry?
How Carbon Intensive is C2I Genomics Inc.'s Location?
C2I Genomics Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
C2I Genomics Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
